Primary Results from Pivotal Phase 3 ACACIA-HCM Trial of Aficamten Presented at ESC Congress 2026

Primary results from the pivotal Phase 3 ACACIA-HCM trial of aficamten, a drug for symptomatic non-obstructive hypertrophic cardiomyopathy, are being presented at the European Society of Cardiology (ESC) Congress 2026. The presentation is part of the "Hot Line 1" session.